AI assistant
DEXCOM INC — Director's Dealing 2024
Apr 16, 2024
30198_dirs_2024-04-16_7e302650-6141-48aa-a3b6-9c8f9121c550.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2024-04-15
Reporting Person: Dolan Matthew Vincent (EVP Strategy and Corporate Dev)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-04-15 | Common Stock | S | 1990 | $137.81 | Disposed | 42377 | Direct |
Footnotes
F1: On December 15, 2023, Mr. Dolan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan.
F2: Included in this number are 40,075 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 3,852 of which were granted on March 8, 2022 and shall vest through March 8, 2025.